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ABSTRACT 
 
Thymidylate synthase (TS) is a fundamental enzyme of nucleotide metabolism and one 
of the oldest anti-cancer targets. Beginning from the analysis of gene array data from 
the NCI-60 panel of cancer cell lines, we identified a significant correlation at both gene 
and protein level between TS and the markers of epithelial-to-mesenchymal transition 
(EMT), a developmental process that allows cancer cells to acquire features of 
aggressiveness, like motility and chemoresistance. TS levels were found to be 
significantly augmented in mesenchymal-like compared to epithelial-like cancer cells, to 
be regulated by EMT induction, and to negatively correlate with micro-RNAs (miRNAs) 
usually expressed in epithelial-like cells and known to actively suppress EMT. 
Transfection of EMT-suppressing miRNAs reduced TS levels, and a specific role for 
miR-375 in targeting the TS 3’-untranslated region was identified. A particularly relevant 
association was found between TS and the powerful EMT driver ZEB1, the shRNA-
mediated knockdown of which up-regulated miR-375 and reduced TS cellular levels. 
The TS-ZEB1 association was confirmed in clinical specimens from lung tumors and in 
a genetic mouse model of pancreatic cancer with ZEB1 deletion. Interestingly, TS itself 
appeared to have a regulatory role on EMT in cancer cells, as TS knockdown could 
directly reduce the EMT phenotype, migratory ability of cells, the expression of stem-like 
markers and chemoresistance. Taken together, these data indicate that the TS enzyme 
is functionally linked with EMT and cancer differentiation, with several potential 
translational implications.  
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INTRODUCTION 
 
Despite the advances made in recent years, for most types of solid tumors only a 
minority of selected patients benefit from molecularly targeted agents, while the majority 
(including relapsing patients) are treated with conventional cytotoxic chemotherapy [1]. 
There is therefore an urgent need for the development of novel drugs and strategies 
based on a better understanding of cancer biology and of the mechanisms of 
chemoresistance. 
Thymidylate synthase (TS) is the enzyme catalyzing the conversion of deoxyuridine 
monophosphate (dUMP) to thymidine monophosphate (dTMP, thymidylate). Since this 
reaction provides the sole de novo pathway for thymidylate production, TS is essential 
for DNA synthesis and repair, and its absence blocks proliferation and causes cell 
death [2]. TS is greatly overexpressed in most cancers and associates with metastatic 
spread and reduced overall survival [3-6]. TS is known as a target of chemotherapy, 
being inhibited by the pyrimidine analogue 5-fluorouracil (5-FU) or by folate analogues. 
Its overexpression in tumors represents a major mechanism of intrinsic 
chemoresistance and, as a result, conventional pharmacological inhibition shows 
limited efficacy [7,8]. Moreover, as an acquired resistance mechanism, TS expression 
levels are rapidly up-regulated following treatment with chemotherapeutic drugs, 
including agents that inhibit its activity [9,10]. Importantly, TS has also been shown to 
function as an oncogene, as stable TS transfection into murine fibroblasts induced a 
transformed phenotype, anchorage-independent growth and tumor formation in nude 
mice [11].  
Epithelial-to-mesenchymal transition (EMT) is a developmental process used by cancer 
cells to acquire a more invasive phenotype [12]. This is accompanied by the loss of 
epithelial polarity (with the reduction of adhesion molecules, like E-cadherin) and the 
acquisition of mesenchymal markers like vimentin, N-cadherin and others, and requires 
the involvement of specific reprogramming factors [13]. EMT has also been implicated 
as a mechanistic motor of cancer stem cells (CSCs) [14], which are undifferentiated 
cancer cells with stem-like features responsible for tumor heterogeneity and for some of 
the most lethal features of cancers [15,16]. The mechanisms behind EMT and CSCs 
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are currently the object of several investigations, with great expectations in terms of 
therapeutic development.  
A few enzymes of nucleotide metabolism and associated pathways have been recently 
functionally connected with EMT and the maintenance of a CSC phenotype [17,18]. We 
therefore aimed at determining a possible correlation between TS and EMT. By data 
mining, cell biology techniques and immunohistochemical staining of tumor samples, 
we identified here an unprecedented association, and described a regulatory axis that 
involves the EMT driver ZEB1 and relevant miRNAs.  
 
METHODS 
 
Cell lines. The hepatocellular carcinoma cell line HepG2 was cultured in EMEM (ATCC, 
Manassas, VA, USA). The colon carcinoma cell lines HCT116 and HT29 were cultured 
in McCoy’s 5A medium (Lonza, Basel, Switzerland), 293T cells were cultured in DMEM 
(Sigma-Aldrich, St. Louis, MO, USA). KPC cells from the mouse model of pancreatic 
ductal adenocarcinoma were cultured in DMEM. All other cells were cultured in RPMI-
1640 (Sigma-Aldrich). All media were supplemented with 10% fetal bovine serum, 1% 
penicillin/streptomycin and 1% L-glutamine (Sigma-Aldrich).  
 
Reagents and antibodies. For Western blotting the antibody for TS (EPR4545) was 
from Abcam (Cambridge, UK); antibodies to E-cadherin (4A2), vimentin (D21H3) and β-
actin (8H10D10) from Cell Signaling (Danvers, MA, USA); anti-ZEB1 (HPA027524) is 
from Sigma-Aldrich; anti-Oct-4 (9B7) and anti-nanog (PA1-097) from Thermo-Fisher 
(Waltham, MA USA). Secondary antibodies were from Southern Biotech (Birmingham, 
AL, USA). Bovine serum albumin is from Carl Roth (Karlsruhe, Germany). Blocking-
grade milk is from BioRad (Hercules, California, USA). Puromycin and propidium iodide 
are from Sigma-Aldrich. 5-fluorouracil powder was reconstituted in DMSO (both from 
Sigma-Aldrich). Cisplatin was obtained from Santa Cruz Biotech (Dallas, TX, USA) and 
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reconstituted in sterile water. Recombinant TGF-β and StemXVivo EMT-inducing 
supplement are from R&D Systems (Minneapolis, MN, USA).  
 
Patients and samples. Formalin-fixed paraffin-embedded surgical specimens of tumor 
tissues of 61 NSCLC patients completely resected between 2005 and 2006 at the San 
Luigi Hospital were consecutively collected. The main characteristics of the patients are 
shown in Figure S8. None of the patients received pre-surgical chemotherapy or 
radiation therapy. All cases were reviewed and classified using anonymized samples. 
The use of retrospective solid tumor tissues for the immunohistochemical study was 
approved by the Research Ethics Committee of the San Luigi Hospital/University of 
Turin (approvals n.167/2015 and 204/2016). 
 
Immunohistochemistry staining and scoring. Tissues were de-waxed, rehydrated 
and processed for staining. Antigen retrieval was performed in a PT-Link pretreatment 
system from Dako (Glostrup, Denmark) for 40 min at 98 °C, using pH 9.0 for TS and 
ZEB1 antibodies and pH 6.0 for E-cadherin. After blocking endogenous peroxidase in 
3% hydrogen peroxide and blocking non-specific sites with 1% BSA for 30 min, the 
slides were incubated for 1 h at room temperature with primary antibodies: TS 
(EPR4545 from Abcam, 1:150 dilution), E-cadherin (36B5 from NeoMarkers/Thermo-
Fisher, 1:30) and ZEB1 (HPA027524 from Sigma-Aldrich, 1:100). The sections were 
then incubated for 40 min with anti-rabbit (TS and ZEB1) or anti-mouse (E-cadherin) 
Dako REAL Envision-HRP. After washing, slides were incubated with DAB for 10 min 
and then counterstained with hematoxylin, dehydrated and mounted. Immunoreactivity 
was evaluated independently by two pathologists by H-score, calculated as follows: H-
score= ΣPi(i + 1), where i represents the intensity of staining (0-3+), and Pi stands for 
the percentage of stained tumor cells (0% to 100%). 
 
Details of other procedures are given in Supplementary materials and methods online.  
 
RESULTS 
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TS levels are increased in cancer cells with a mesenchymal phenotype 
We analyzed the publicly available mRNA array data obtained from the NCI-60 panel of 
cancer cell lines (Stanford, Novartis and U133 databases). These cells have been 
previously independently determined to be of epithelial (n=11) or mesenchymal (n=37) 
nature by western blot quantification [19], and a significantly higher expression of TS 
(the TYMS gene) in mesenchymal-differentiated cells in all databases was found (see 
the data from the Stanford database in Figure 1A and from Novartis in Figure S1A). 
Consistently, an inverse correlation between TS and epithelial markers E-cadherin 
(CDH1) and micro-RNA-200c (miR-200c) and a positive correlation between TS and 
mesenchymal marker ZEB1 at the gene expression level in the same datasets were 
found, Figure S1B. The observation was also confirmed by generating a gene ratio 
(vimentin/E-cadherin) from the same datasets, which we validated as significantly 
correlating with the EMT status of the NCI-60 cells (Figure S1B and not shown). To 
further validate this observation at the protein level, we subjected a panel of 18 cancer 
cell lines (mostly belonging to the NCI-60 panel and cultured in the same media and 
conditions) to a western blot analysis for TS and EMT markers, including E-cadherin, 
vimentin and ZEB1. As a result, a high variability in TS levels was found among the 
different cell lines, ranging from almost non-detectable to very high (Figure 1C). With 
regards to the association with the EMT status, even if some individual cases failed to fit 
in the TS-EMT correlation, we were able to confirm that cells with a mesenchymal-like 
phenotype (M-like cells, with low E-cadherin and high vimentin/ZEB1 levels) had an 
increased TS expression, compared to E-like cells (Figure 1D). To further confirm these 
data, we extracted the TS proteomic data from a publicly available online database [20] 
and analyzed the protein levels obtained from NCI-60 cancer cells (n=32). The results 
again indicated an increased expression of TS in cancer cells classified as M-like, and 
this difference was found to be significant (Figure S1C-E). Cancer cells with an M-like 
phenotype are representative of tumors with an increased aggressiveness [14,21], and 
TS is required for the proliferation of cells [2,8]. In order to rule out that the observed 
higher TS levels in cells that have undergone EMT could have been attributable to an 
increased proliferation rate of the M-like cells, we analyzed the gene-array data 
searching for associations between well-established cancer proliferation markers (Ki67, 
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cyclin-D1, PCNA and others as previously characterized [22]). However, no correlation 
between expression levels of other proliferation genes and EMT status of the cells was 
found (Figure S2A). Indeed, by the analysis of the doubling times data, we could 
exclude that the increased TS levels in M-like cells of the NCI-60 cells were due to an 
increased proliferation rate (Figure S2B). In synthesis, cancer cells with an M-like 
status show increased TS levels, not likely attributable to a differential proliferation rate. 
 
TS levels are associated with ZEB1 
By the analysis of both mRNA and protein levels a strong positive correlation between 
TS and ZEB1 was observed (quantification in Figure 1E). ZEB1 is a powerful 
transcriptional regulator and can serve as a master regulator of EMT in cancer cells, by 
directly suppressing or activating EMT-related genes [23,24]. We therefore aimed at 
further investigating the nature of this association. First, since the NCI-60 group 
encompasses different tumor types, we aimed at determining if the TS-ZEB1 correlation 
was retained in cells from a single tumor type. In a panel of seven NSCLC cells, 
western blot analysis showed a higher TS expression in cells with increased ZEB1 
levels (Figure 1F). To explore the basis for this relationship, we used a shRNA-
mediated knockdown approach to suppress ZEB1 in lung adenocarcinoma A549 cells, 
which are of an intermediate EMT status [19].  Stably infected cells showed a significant 
reduction of ZEB1 levels and a robust suppression of EMT, as evidenced by the 
reduced vimentin and the increase in E-cadherin (Figure 1G). The occurrence of MET 
(the opposite of EMT) was also confirmed by immunofluorescence for EMT markers 
(Figure S3A). Importantly, TS protein levels were also significantly reduced by ZEB1 
knockdown (Figure 1G), suggesting the existence of a possible functional association 
between ZEB1 and TS. However, TS and vimentin mRNA levels evaluated by RT-qPCR 
were not found to be reduced (Figure 1H), suggesting that the suppression induced by 
shZEB1 was not at the transcript level.  
Protein lysates of cell lines derived from tumors from a genetically engineered mouse 
model of pancreatic cancer, KrasG12D;Trp53R172H;Pdx1-Cre (KPC) or from the ZEB1 
knockout counterpart, called KPCZ, recently generated (Krebs et al., personal 
communication) were additionally tested. As a result, KPCZ cells exhibited an E-like 
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phenotype and significantly lower TS levels than KPC. The association was also found 
among KPC cells with different EMT status (Figure S3B-C). In order to test the 
possibility that ZEB1 can directly regulate TS expression, a doxycyclin-inducible system 
to overexpress ZEB1 was used in MCF-10A cells [25]. However, ZEB1 overexpression 
did not change TS levels in these cells (Figure S3D) and similar results were obtained 
transiently overexpressing ZEB1 in A549 and other cancer cells (not shown). We 
therefore concluded that ZEB1 regulates TS in an indirect fashion.    
 
EMT can induce TS and mesenchymal cells are more resistant to TS inhibition 
Increased TS levels are associated with resistance to TS-inhibiting agents [2,8]. To test 
a differential sensitivity of cells with an established EMT status, we again analyzed the 
datasets from the NCI-60 panel [26]. 5-fluorouracil sensitivity data were extracted from 
two chemical screens and the cells divided by EMT status, according to the VIM/CDH1 
gene ratio. The results indicated significantly greater resistance in cells with an M-like 
phenotype (Figure 2A-B). To validate these data in our cells, we matched E-like and M-
like cells from eight cell lines of four different origins (breast, lung, colon and ovarian) 
and evaluated the relative 5-FU sensitivity by death assays with IC50 calculations. A 
lower rate of viable cells was consistently observed in E-like cells (Figure 2C-D) and 
this was confirmed by death assays (Figure 2E-F and Figure S4A). To confirm that 
EMT could be partly responsible for increased TS expression, A549 cells were 
subjected to EMT induction by treatment with TGF-β (Figure 2G) or by StemXVivo EMT 
inducing media supplement (Figure S4B), and in both cases we could detect a 
transitory increase in TS levels. Also, a significant increase in 5-FU resistance was 
found in TGF-β treated cells (Figure 2H). To further link TS with cancer cells’ EMT, we 
analyzed gene datasets from the GEO repository and found that TGF-β treatment in 
immortalized bronchial epithelial cell (Figure S4C) and that overexpression of four 
independent EMT factors in human mammary epithelial cells [27] (Figure S4D) could 
significantly increase TS levels. Conversely, gene array data [28] from breast cancer 
cells with enforced overexpression of the EMT-suppressing miRNA miR-200c [19,21,23] 
produced a significant reduction of TS mRNA expression (Figure S4E). All together 
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these data support the existence of a connection between TS and EMT, with the indirect 
role of ZEB1. 
 
EMT-suppressing miRNAs reduce TS 
Micro-RNAs can suppress the expression of genes by targeting their 3’ untranslated 
regions (UTR), and they have been described as strong regulators of EMT and stem-
like features of cancer [12]. For a preliminary check of whether the TS 3’-UTR was 
targeted by miRNAs (or by other 3’-UTR-targeting elements) as previously indicated 
[29], we transfected a luciferase reporter plasmid containing the full-length TS 3’-UTR 
into A549 cells. We obtained a significant reduction of luciferase activity compared to a 
control plasmid (Figure 3A), suggesting a degree of targeting (not sufficient to 
completely abrogate TS protein expression). A similar result was also obtained by 
cloning the 3’-UTR sequence downstream of the stop codon of dsRed in a Red-
expressing plasmid (Figure S5A). We then used a bioinformatic approach [30] to 
identify the miRNAs that most significantly negatively correlated with TS gene 
expression; the top hits were EMT-suppressing miRNAs (data on NCI-60 cells, Figure 
S5B), the miR-200s, miR-203, miR-215, and miR-375 [31-34]. The last three miRNAs 
also displayed potential seed matches in the TYMS 3’-UTR (Figure 3B), and two of 
them (miR-215 and miR-203) have been already reported as targeting TS [29,35]. 
Further confirmation of the role of these miRNAs in EMT was found by checking the 
correlation scores with E-cadherin and vimentin (Figure 3C). To check if these miRNAs 
could effectively reduce TS levels, we performed pre-miRNA transfection experiments in 
HCT116 and HeyA8, colon and ovarian cancer cells (intermediate-EMT and M-like 
status, respectively) with high TS levels, using miR-200a and miR-200c as positive 
control for EMT suppression. By western blotting it was observed that most of these 
miRNAs could significantly reduce TS levels, and that miR-375 had the strongest 
activity (Figure 3D-E). EMT suppression was confirmed by ZEB1 reduction and 
restoration of E-cadherin expression. HCT116 cells have lower miR-375 than other 
colon cancer cells (Figure S6A-B) and higher TS levels (Figure 1C). A luciferase 
reporter assay confirmed that the suppression was at the level of the 3’-UTR and the 
predominant role for miR-375 (Figure 3F).  
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ZEB1 regulates TS through miR-375 
To establish TS as a specific target of miR-375, we mutated the TS 3’-UTR in the seed 
match region and found that the mutated sequence could not be suppressed by miR-
375 (Figure 3G). Consistently, miR-375 was found to sensitize the cells to 5-FU by 
specific TS inhibition (Figure S6C-D). Since miR-375 has been described as negatively 
regulated by ZEB1 [36,37], we measured miR-375 in A549 cells with ZEB1 knockdown, 
and found a dramatic increase relative to control-infected cells (Figure 3H). miR-203, 
another TS-targeting miRNA suppressed by ZEB1 [35,38], was also increased in 
shZEB1 cells (2.5-fold, not shown). Pre-miR-375 transfection into the parental A549 
cells strongly reduced TS, while miR-375 inhibition with antagonistic miRNA in shZEB1 
cells restored TS levels (Figure 3I-J). These results confirmed the specificity and the 
significance of miR-375 in TS regulation, indicating the indirect involvement of ZEB1.  
 
TS can promote EMT and ZEB1 expression 
To test a direct role of TS on EMT, we established a TS knockdown using two 
independent shRNA sequences. Western blots showed that A549 cells increased the 
expression of epithelial and reduced that of mesenchymal markers compared to 
scrambled-infected (PLKO) cells (Figure 4A). In line with the connection between EMT 
and CSCs, CSC markers like Oct-4 and Nanog were also reduced in shTS cells. 
Immunofluorescence staining confirmed the EMT suppression, with reduced vimentin 
and increased E-cadherin expression (Figure 4B). Since TS elimination can induce 
death, we verified that the observed phenomenon was not attributable solely to a 
differential sensitivity of E-like and M-like cells to TS suppression; a death assay by PI 
staining showed minimal or no death associated with TS knockdown (Figure 4C and 
Figure S7A). Proliferation rate, monitored by MTS and by an Incucyte real-time 
proliferation assay, was reduced by the shTS#2 sequence, only, but not the shTS#1 
(not shown). Therefore, the observed effects of TS knockdown on EMT are not related 
to a defect in proliferation. However, a colony-formation assay indicated a reduced 
number of colonies also from the shTS#1, suggesting that the cells´ aggressiveness 
was reduced (Figure 4D).  
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Along with the expression of specific markers and reduction of colony formation ability, 
another hallmark of EMT is the acquisition of a highly migratory phenotype. We 
therefore analyzed if TS suppression had an impact on cells’ motility. A wound-healing 
assay indicated that shTS cells had impaired migration (Figure 4E-F). This was also 
independently confirmed by a real-time migration assay, analyzing the results with a 
matrix (relative wound density) that normalizes for the cells´ proliferation (Figure 4G). 
 
Another important feature of EMT is the acquisition of chemoresistance, and a real-time 
death assay staining cells with a green cytotoxicity reagent indicated a significant higher 
sensitivity of A549-shTS cells to the chemotherapeutic drug cisplatin (Figure 4H). High 
ALDH1 activity/expression (ALDH1high) has been previously reported to mark a 
subpopulation of cells with the features of CSCs [39]. In light of the strong connection 
between EMT and CSCs, we also aimed at identifying a connection between TS and 
stemness markers. siRNA-mediated knockdown of A549 cells reduced the percentage 
of ALDH1high cells (Figure 4I-J), and the ability of the cells to grow in sphere-forming 
conditions in low-attachment dishes (Figure 4K), a common readout of cancer 
stemness, in the absence of a dramatic reduction of the cell’s ability to proliferate and 
grow (Figure S7B). A cell-sorting experiment confirmed increased TS levels in 
ALDH1high cells (Figure S7C). Similar results were also found in shTS cells (Figure 
S7D-E). As a further experiment to directly investigate the role of TS in cancer EMT and 
stemness, we stably overexpressed TS and we conversely found a reduction in E-
cadherin and a significant increase in ZEB1 protein levels and in the relative proportion 
of ALDH1high cells (Figure 4L-M), as well as an increase in sphere-forming ability 
(Figure S7F). Finally, in order to validate the role for TS in EMT and cancer stemness in 
another cellular system, we subjected a pancreatic cancer cell line from the KPC model 
to similar experimental approaches, and found similar results (Figure S7G-J).  
 
5-FU can induce EMT and ZEB1 in a TS-dependent manner 
Chemoresistance to TS-inhibiting drugs like 5-FU [40,41] or pemetrexed [42,43], has 
been shown to involve the EMT program, and TS levels are known to be increased 
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following treatment with TS-inhibiting drugs [8,10,43,44]. To test a direct connection 
between TS levels and drug-related EMT, we established an EMT-induction model in 
vitro by treating the cancer cells with increasing doses of 5-FU (Figure 5A) and 
confirmed the occurrence of the EMT phenotype (Figure 5B-C). Western blot analysis 
indicated that TS levels were significantly increased in the treated cells, along with EMT 
markers, while this increase was attenuated in shTS cells (Figure 5C). Of note, TS 
knockdown cells could still increase TS levels (although to a lower extent) indicating that 
such increase is only partially occurring at a transcriptional level, as previously 
described [45]. Interestingly, ZEB1 was found not regulated by the drug treatment in 
cells with TS stable knockdown, and Aldefluor staining (Figure 5D) and sphere 
formation assay (Figure 5E) confirmed for these cells that the number of CSCs was 
significantly reduced. 
 
TS levels are associated with EMT markers in non-small cell lung cancer tissues 
and are highly prognostically relevant 
To test the association between TS and ZEB1 in cancer specimens, we performed an 
immunohistochemical analysis of TS, ZEB1 and E-cadherin in cancerous tissues from 
61 consecutive NSCLC patients (Figure S8A). Mean TS and ZEB1 levels were 50.5 (0-
210) and 18.75 (0-140, all IHC scores), respectively. Dividing the patients according to 
ZEB1 expression (negative tumors compared to those with IHC score >5), higher TS 
levels were identified in ZEB1-positive tumors (Figure 6A) consistent with the in vitro 
observations. Tumors with concomitant high co-expression of TS and ZEB1 were 
predominantly of the squamous cell carcinoma histotype (p<0.01). Dividing patients 
according to E-cadherin negativity (either negative or cytoplasmic diffuse staining 
pattern) or positivity (membrane pattern of staining), as previously done [21], we also 
found significantly reduced TS levels in E-cadherin positive tumors (Figure 6B-C). 
Further dividing the patients by histology (adenocarcinoma vs. squamous-cell 
carcinoma), this association was significant only in patients with lung adenocarcinoma. 
This is probably due to the higher baseline TS in squamous-cell carcinomas [46]. No 
other significant association was found between the available clinical information, with 
the exception of a trend (p=0.06) for an association with grade of differentiation and 
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increased TS IHC score (Figure S8B). Analysis of survival on a large dataset of NSCLC 
patients [47] indicated the high prognostic relevance of TS and E-cadherin (in an 
opposite trend, Figure 6D) in adenocarcinoma patients, only, suggesting a biological 
relevance of this association in this tumor type.  
 
DISCUSSION 
 
Our data highlight the role of TS in cancer differentiation and EMT, showing the 
functional association with ZEB1 and the involvement of miRNAs, providing possible 
insights into the clinically observed connection between increased TS levels and local 
and distant metastatic spread in cancer patients [3,4,48,49].  
 
We demonstrated significantly higher TS level in cancer cells with an M-like phenotype, 
not attributable to an increased propensity of these cells to proliferate. A comparative 
analysis of TS protein in cancer cells revealed that the expression levels could vary very 
significantly, and indicated that some remarkable cells have almost non-detectable 
expression (Figure 1C). Considering that TS is life-essential, this may indicate that 
minimal baseline enzyme expression is sufficient for the cells’ metabolic requirements, 
purporting that the additional levels could be implicated in other biological functions. A 
significant association between TS and ZEB1, a powerful EMT-inducing transcription 
factor, was identified and confirmed in tumor samples. However, ZEB1 was not 
identified as a direct modulator of TS expression by functional assays. Searching for 
possible mechanisms behind the association between TS and EMT, we found that 
several EMT-suppressing miRNAs could reduce TS and we identified and validated 
miR-375 as a novel TS-targeting miRNA. The fact that multiple independent miRNAs 
involved in EMT can target TS further highlights the importance of its regulation in 
cancer differentiation. ZEB1 is known to repress EMT-suppressing miRNAs, like miR-
200, miR-203 or miR-375 [24,36,37], and we found that ZEB1 knockdown up-regulated 
miR-375 and reduced TS expression. TS-ZEB1 co-expression may therefore be 
sustained by regulatory circuits involving miRNAs. Interestingly, we found that TS itself 
possesses EMT-regulating properties and can induce ZEB1. Since all the players 
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involved in this reciprocal regulation can be simultaneously co-expressed, especially in 
cells with an intermediate-EMT status like A549, it is reasonable to speculate the 
existence of a molecular equilibrium, which can be rapidly unbalanced upon EMT 
induction (Figure 5F). Overall, these data represent an initial step into a better 
description of the previously identified role of TS in tumorigenesis [11]. Further 
investigations are needed to explore the possible involvement of other EMT 
transcription factors on TS regulation, and to determine the exact contribution of 
nucleotide metabolism to stemness and EMT, as previously found [17,18]. Finally, we 
confirmed recent reports showing the occurrence of EMT in cells overexpressing TS 
after treatment with TS inhibitors [42,43], and we found that the transformation was 
attenuated by TS knockdown (Figure 5). These results, in the long run, may inspire the 
design and the clinical implementation of novel improved drugs (like small molecules 
inhibitors or gene-targeting agents) targeting TS without triggering its expression. With 
regards to possible translational implications, the EMT status of the tumors (particularly 
in lung adenocarcinoma) could be tested as stratification criteria for administering TS-
inhibiting drugs.  
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FIGURE LEGENDS 
 
Figure 1. TS levels are increased in cells with a mesenchymal-like phenotype. (A) Log-
transformed TS (TYMS) mRNA expression levels in epithelial (green) and 
mesenchymal-like (red) cancer cell lines from the NCI-60 Stanford array dataset. Lines 
indicate median levels in both groups. (B) Correlation between E-cadherin (CDH1), 
ZEB1 and miR-200c and the TYMS gene. R-values are Pearson coefficients. (C) 
Western blot analysis of TS protein levels and EMT markers in cancer cells. β-actin is 
used as a loading control. (D) Densitometric quantification (ImageJ) of TS levels 
expressed as ratios with β-actin in the western blots as in (C). (E) Quantification of TS 
levels expressed as band area intensity in the western blots as in (C), dividing for ZEB1 
negativity or positivity. (F) Western blot analysis of TS and ZEB1 in a panel of non-small 
cell lung cancer (NSCLC) cell lines. (G) Western blot analysis of TS and EMT markers 
in A549 cells stably overexpressing a scrambled control or a shRNA targeting ZEB1. (H) 
qPCR analysis of EMT markers and TS in shZEB1 and control A549 cells. Data are 
±SD, normalized to GAPDH and expressed as -fold-change relative to control cells. P-
values are two-tailed t-tests; ** indicates p<0.01. 
 
Figure 2. A mesenchymal-like phenotype and higher TS levels are associated with 
increased 5-FU resistance. (A) Sensitivity of NCI-60 cancer cell lines to 5-FU, 
expressed as log-transformed values. Cells were divided into Epithelial, Mesenchymal 
Low and Mesenchymal High, according to a pre-determined EMT gene ratio. Data are 
from DTP of the National Cancer Institute (NCI). (B) IC50 values of NCI-60 cancer cell 
lines relative to 5-FU. Data are from the GI50 database (NCI). (C) Representative 
images of breast (MDAMB231, T47D), colorectal (HCT116, KM12), lung (A549, Calu-1) 
and ovarian (Ovcar5, Ovcar8) cancer cells treated with the indicated concentrations of 
the drug. (D) Dose-response curves and IC50 calculations of cells as in (C) treated for 
48 hours with the indicated concentrations of 5-FU. Numbers indicate IC50 values ±SD. 
Percentage of dead cells were calculated with FACS dead/live cells gating in 
quadruplicate conditions. (E) FACS plots of Ovcar8 and Ovcar5 cells treated with 1 mM 
5-FU and stained after 48 h with PI (Nicoletti). Indicated are percentages subG1 fraction 
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(gated). (F) Quantification of percentage of subG1 fraction, in cells treated as in (E). (G) 
Western blot of E-cadherin, ZEB1 and TS in A549 cells treated for 48 h with 10 ng/µl 
TGF-β. (H) Percentage of viable cells in A549 cells treated and untreated with 10 ng/µl 
TGF-β and with 5-FU or control for the indicated time-points. All non-treated controls 
were given DMSO concentrations equivalent to the highest 5-FU administered dose. 
NT= non-treated and P-values are two-tailed t-tests, * indicates p<0.05.   
 
Figure 3. EMT-suppressing miRNAs can inhibit TS expression. (A) Relative luciferase 
activity of A549 cells transiently transfected with Psicheck2 plasmid carrying the full-
length TS 3’-UTR or the control empty plasmid. (B) Sequence of the TS 3’-UTR starting 
at the stop codon. Indicated are the seed regions complementary to the indicated 
miRNAs: miR-215, miR-203 and miR-375. (C) Correlation scores of miR-203, miR-215 
and miR-375 with the mRNA expression levels of E-cadherin (CDH1 gene) and vimentin 
(VIM). Data from CellMiner.com and correlation scores are according to Pearson. (D) 
Western blot analysis of TS, ZEB1 and E-Cadherin in HCT116 and (E) HeyA8 cells 72 h 
after transfection with the pre-miR-control, pre-miR-200a, pre-miR-200c, pre-miR-203, 
pre-miR-215 and pre-miR-375 at 50 nM concentration. (F) Relative luciferase activity of 
293T cells transiently transfected with the Psicheck2 plasmid carrying the full-length TS 
3’-UTR, and co-transfected with pre-miR-control, pre-miR-200a, pre-miR-200c, pre-miR-
203, pre-miR-215 and pre-miR-375 at 50 nM concentration, 48 h after transfection. (G) 
Relative luciferase activity of 293T cells transiently transfected with the Psicheck2 
plasmid carrying the full-length TS 3’UTR or with the sequence mutated in the miR-375 
seed region, co-transfected with pre-miR-control or pre-miR-375. (H) qPCR 
quantification of miR-375 levels in A549 cells stably overexpressing an shRNA targeting 
ZEB1, relative to the control cells. (I) Western blot quantification of TS and ZEB1 levels 
in A549 cells after pre-miR-375 transfection, compared to control-transfected cells. (J) 
Western blot quantification of TS and ZEB1 levels in shZEB1-A549 cells after anti-miR-
375 transfection, compared to control-transfected cells. P-values are two-tailed t-tests (* 
indicates p<0.05, ** indicates p<0.01).    
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Figure 4. TS suppression by shRNA reduces EMT and the migratory phenotype. (A) 
Western blot analysis of TS and indicated EMT and CSCs markers in A549 cells 
infected with shRNA targeting two independent TS mRNA sequences, compared to 
scrambled-infected cells (PLKO). (B) Immunofluorescence on A549 cells stably 
overexpressing a scrambled control or a shRNA targeting TS, stained for E-cadherin 
and vimentin. The cells were stained concomitantly with the shZEB1 shown in the 
Figure S3A, with the same PLKO cells as control. DAPI is used as a nuclear 
counterstain. (C) FACS plots of cells as in (A) 6 days after infection stained with PI 
(Nicoletti). Indicated are percentages of subG1 nuclei. (D) Colony formation of cells as 
in (A) stained after 7 d with crystal violet and quantified in triplicate dishes. (E) 
Representative pictures and (F) quantification of wound-healing assay on A549 cells 
infected with non-targeting or with shTS overexpressing viruses. (G) Plots of relative 
wound densities of A549 cells infected with non-targeting or with shTS and shZEB1 
overexpressing viruses. (H) Real-time analysis of cell death in A549 cells infected with 
non-targeting or with shTS and shZEB1 overexpressing viruses after treatment with 
Cisplatin (CDDP) at 750 µM dose. Cell death was monitored with the incorporation of a 
green dye by Incucyte ZOOM system. (I) Western blot analysis on TS in A549 cells 
transfected with siRNA smart pool targeting TS, compared to non-targeting control cells. 
(J) FACS plots of cells as in (I) and stained with Aldefluor reagent, to quantify the 
percentage of CSCs cells. Gates were set using DEAB reagent; percentages indicate 
the proportion of ALDH1high cells. (K) Quantification of sphere number in cells treated as 
in (I) and plated in sphere-forming conditions in low-adherence plates. (L) Western blot 
analysis on TS, ZEB1 and E-Cadherin in A549 cells infected with a vector 
overexpressing TS, compared to control-infected cells. (M) FACS plots of cells as in (L) 
and stained with Aldefluor reagent. P-values are two-tailed t-tests (* indicates p<0.05, ** 
indicates p<0.01).    
 
Figure 5. 5-FU treatment induces EMT and increases TS levels, which are required for 
ZEB1 activation. (A) Scheme of the EMT induction via long-term 5-FU treatment in 
A549 cells. Pictures show the shape of the cells treated with increasing concentration of 
5-FU, up to 10 µM, and cells treated with DMSO (NT) after one week of growth in 
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normal media. (B) Immunofluorescence on cells treated as in (A), stained for E-cadherin 
and vimentin. DAPI is used as a nuclear counterstain. (C) Western blot analysis on 
PLKO and shTS A549 cells treated as indicated in (A) and analyzed for the protein 
levels of EMT and CSCs markers. (D) FACS plots of cells as in (C) and stained with 
Aldefluor reagent, to quantify the percentage of CSCs cells. (E) Quantification of 
spheres number in cells treated as in (C) and plated in sphere-forming conditions in low-
adherence plates. P-values are two-tailed t-tests (* indicates p<0.05). (F) Scheme of the 
proposed model behind TS and ZEB1 association in cancer cells, in which TS, ZEB1 
and miRNAs belong to an EMT regulatory loop. EMT-suppressing miRNAs can target 
TS and ZEB1. Upon EMT, induced for instance by 5-FU treatment, TS and ZEB1 levels 
are increased and EMT-suppressing miRNAs are object of ZEB1 inhibition.  
 
Figure 6. TS protein levels are associated with ZEB1 and E-Cadherin in NSCLC 
tissues. (A) Quantification of TS expression levels in tissues from 61 NSCLC patients. 
Patients were divided into two groups according to ZEB1 IHC positivity or negativity. (B) 
Quantification of TS expression levels in tissues from NSCLC patients. Patients were 
divided into two groups according to E-cadherin IHC negativity (either negative or 
cytoplasmic diffuse staining pattern) or positivity (membrane pattern of staining). 
Patients were further divided in adenocarcinoma (ADC) and squamous cell-carcinoma 
(SSC). The p-values are from a Mann-Whitney U test. (C) Representative microscopic 
images of a NSCLC case with high (#1) and low (#2) TS staining, with corresponding 
staining of E-cadherin and ZEB1. D) Survival curves of NSCLC patients divided by high 
and low expression of TS (TYMS gene) and E-cadherin (CDH1 gene) from a 
transcriptomic database and divided for histological diagnosis (ADC and SSC). P-values 
indicated are log-rank, and ns=non-significant.    
 






